Dr. Robert A. Fenstermaker, MD

Dr. Fenstermaker practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Fenstermaker's NPI, 1376549683, was assigned on June 22, 2005. Dr. Fenstermaker graduated from Northeast Ohio Medical University in 1981. Dr. Fenstermaker holds New York license 197873.

Dr. Fenstermaker's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Fenstermaker's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Fenstermaker is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fenstermaker practices. Vendor and product names are available with a free account.

Neurological surgery is Dr. Fenstermaker's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Fenstermaker is board certified in neurological surgery by the American Board of Neurological Surgery. Dmand AI has Dr. Fenstermaker's licenses on file in 2 states: New York and Ohio.

Dmand AI lists craniotomy among the conditions Dr. Fenstermaker treats.

CMS data shows 46 Medicare services from Dr. Fenstermaker across 2 procedure codes in 2024, for 31 Medicare patients. Medicare paid $19,817 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 31 Medicare patients who saw Dr. Fenstermaker in 2024. The largest group is 65 to 74, with 15 patients. 75% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fenstermaker's median patient age at 69, with 62% women.

In 2017, Dr. Fenstermaker wrote 11 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $176 in total drug cost.

Dr. Fenstermaker accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 94 papers to Dr. Fenstermaker, published from 2004 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Brain Neoplasms, Glioma and ErbB Receptors. Dr. Fenstermaker has published most often in J Neurooncol. Dr. Fenstermaker's most frequent co-authors are Andrew Joseph Fabiano, MD, Rolf F. Barth, MD and Dheerendra Prasad, MD.

Dmand AI links Dr. Fenstermaker to 6 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Glioblastoma, Gliosarcoma and Astrocytoma. Roswell Park Cancer Institute sponsors the most, 3.

CMS Open Payments shows 2 general payments to Dr. Fenstermaker from 2 drug and device companies from 2018 to 2022. Food and beverage make up the largest share, 53% of the total. Medtronic USA, Inc. paid the most, $112.

Dmand AI lists 5 awards for Dr. Fenstermaker, most recently America's Top Doctors in 2022.

Dr. Fenstermaker graduated from Northeast Ohio Medical University in 1981. Dr. Fenstermaker is a member of AANS, ACS and CNS.

Dr. Fenstermaker is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.